Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Receivables - Accured: 2022-2025

Historic Receivables - Accured for Crinetics Pharmaceuticals (CRNX) over the last 1 years, with Sep 2025 value amounting to $6.3 million.

  • Crinetics Pharmaceuticals' Receivables - Accured was N/A to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year change of. This contributed to the annual value of $8.3 million for FY2024, which is 167.74% up from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Receivables - Accured of $6.3 million as of Q3 2025, which was down 25.00% from $8.4 million recorded in Q2 2025.
  • Crinetics Pharmaceuticals' Receivables - Accured's 5-year high stood at $8.4 million during Q2 2025, with a 5-year trough of $1.4 million in Q4 2022.
  • For the 3-year period, Crinetics Pharmaceuticals' Receivables - Accured averaged around $6.7 million, with its median value being $7.2 million (2025).
  • Data for Crinetics Pharmaceuticals' Receivables - Accured shows a peak YoY surged of 167.74% (in 2024) over the last 5 years.
  • Crinetics Pharmaceuticals' Receivables - Accured (Quarterly) stood at $1.4 million in 2022, then skyrocketed by 121.43% to $3.1 million in 2023, then spiked by 167.74% to $8.3 million in 2024, then reached $6.3 million in 2025.
  • Its Receivables - Accured was $6.3 million in Q3 2025, compared to $8.4 million in Q2 2025 and $7.2 million in Q1 2025.